SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that following completion of Cohort 4 which expanded the 3.0 mcg, 6.0 mcg, and 12.0 mcg/kg dose cohorts by an additional 9 patients, the Company has initiated enrollment of its fifth and final cohort (Cohort 5) in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA). PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A.
Help employers find you! Check out all the jobs and post your resume.
